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In Brief
In the face of irreparable DNA damage,
cells eventually overcome the DNA dam-
age checkpoint and continue to divide
(checkpoint adaptation). Checkpoint
escape can lead to chromosomal aberra-
tions and may have detrimental out-
comes. Klermund et al. now find that the
propensity to adapt depends on nutri-
tional status and hence TORC1 activity.
They show that TORC1 inhibition pre-
vents checkpoint adaptation and there-
fore maintains cell viability following
chronic telomere dysfunction.
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Cells challenged with DNA damage activate check-
points to arrest the cell cycle and allow time for
repair. Successful repair coupled to subsequent
checkpoint inactivation is referred to as recovery.
When DNA damage cannot be repaired, a choice be-
tween permanent arrest and cycling in the presence
of damage (checkpoint adaptation) must be made.
While permanent arrest jeopardizes future lineages,
continued proliferation is associated with the risk
of genome instability. We demonstrate that nutri-
tional signaling through target of rapamycin complex
1 (TORC1) influences the outcome of this decision.
Rapamycin-mediated TORC1 inhibition prevents
checkpoint adaptation via both Cdc5 inactivation
and autophagy induction. Preventing adaptation re-
sults in increased cell viability and hence proliferative
potential. In accordance, the ability of rapamycin to
increase longevity is dependent upon the DNA dam-
age checkpoint. The crosstalk between TORC1 and
the DNA damage checkpoint may have important
implications in terms of therapeutic alternatives for
diseases associated with genome instability.
INTRODUCTION
Checkpoints prevent cell cycle progression in the presence
of damaged DNA (Zhou and Elledge, 2000), thereby allowing
time for repair to occur while simultaneously preventing lethal/
pathogenic genetic alterations from being propagated into
subsequent generations. Consistently, checkpoints provide a
barrier to cancer development (Kastan and Bartek, 2004; Sperka
et al., 2012).
Double-strand breaks (DSBs) are particularly toxic DNA le-
sions because of their propensity to promote genome rearrange-
ments. The response to a DSB is initiated by exonuclease-medi-
ated resection of the newly exposed DNA ends, which generates
30 single-stranded (ss) DNA that becomes bound by the replica-
tion protein A complex (RPA) (Dewar and Lydall, 2012; Garvik
et al., 1995; Lee et al., 1998; Mimitou and Symington, 2008). In
budding yeast (S. cerevisiae), RPA recruits Ddc2 (ATRIP) and324 Cell Reports 9, 324–335, October 9, 2014 ª2014 The AuthorsMec1 (ATR/ATM), which activate the downstream effectors
Chk1 and Rad53 (CHK2) to elicit a G2/M arrest (Sanchez et al.,
1999; Weinert et al., 1994). Chk1 contributes to this arrest
by stabilizing Pds1 (securin), which prevents Esp1 (separase)
from cleaving the Scc1 subunit of cohesin and as a result
hinders the onset of anaphase A (Agarwal et al., 2003; Ciosk
et al., 1998). Rad53, in addition to contributing to Pds1 stabili-
zation, inactivates the polo-like kinase, Cdc5 (PLK1), a positive
regulator of multiple mitotic events, including spindle elongation
(Zhang et al., 2009) and the mitotic exit network (MEN) (Hu et al.,
2001).
Telomeres make up the ends of linear chromosomes and are
structurally similar to DSBs. In contrast to DSBs, they are
neither subject to repair nor do they activate the DNA damage
checkpoint (de Lange, 2009). Telomeres terminate in a 30 ss
overhang, which in S. cerevisiae is bound by the CST
(Cdc13-Stn1-Ten1) complex that caps and protects chromo-
some ends (Garvik et al., 1995; Giraud-Panis et al., 2010; Gran-
din et al., 2001). Upon CST inactivation, ssDNA accumulates
due to 50strand resection by the exonuclease, Exo1 (Maringele
and Lydall, 2002). Similar to DSB processing, the accumulation
of telomeric ssDNA elicits a Mec1/Rad53-orchestrated DNA
damage response (DDR), which prevents subsequent mitotic
events (Garvik et al., 1995; Lydall and Weinert, 1995; Zubko
et al., 2004).
When DSBs and dysfunctional telomeres are repaired, the
checkpoint signal is attenuated allowing mitotic progression
and passage into the succeeding G1, a process referred to as
recovery (Cle´menson and Marsolier-Kergoat, 2009; van Vugt
and Medema, 2004; Vaze et al., 2002). Although repair and
recovery represent the preferred outcome following DNA dam-
age, an alternative solution exists. In the presence of irreparable
DNA damage/telomere dysfunction, budding yeast eventually
inactivate the DNA damage checkpoint and proceed through
mitosis despite damage persistence—a phenomenon known
as checkpoint adaptation (Pellicioli et al., 2001; Sandell and
Zakian, 1993; Toczyski et al., 1997). In a screen to identify regu-
lators of adaptation, the polo-like kinase Cdc5 emerged as a
promoting factor. Cells expressing an adaptation-defective
mutant allele of CDC5 (cdc5-ad) fail to adapt (Toczyski et al.,
1997), whereas the overexpression of Cdc5 accelerates adapta-
tion (Donnianni et al., 2010; Lopez-Mosqueda et al., 2010;
Vidanes et al., 2010). Although adaptation offers cells the oppor-
tunity to recommence proliferation more quickly in the face of
irreparable damage, it is associated with the risk of increased
genome instability and chromosome loss (Galgoczy and Toczy-
ski, 2001; Sandell and Zakian, 1993).
Target of rapamycin complex 1 (TORC1) controls cell growth.
In nutrient-rich conditions, TORC1 is active and promotes
anabolic pathways via growth-promoting transcription pro-
grams, translation initiation, and ribosome biogenesis, while at
the same time inhibiting catabolic processes such as autophagy
(Loewith and Hall, 2011). Rapamycin is a lipophilic macrocyclic
lactone that inhibits TORC1 (Zheng et al., 1995; Wullschleger
et al., 2006) and hence mimics nutrient starvation. TORC1 activ-
ity promotes the transition from G1 to S as rapamycin-treated
cells accumulate in G1 (Barbet et al., 1996). Recent evidence,
however, has demonstrated that TORC1 also influences the
G2/M transition by regulating Cdc5 localization (Nakashima
et al., 2008). Moreover, it was shown that the induction of auto-
phagy is sufficient to prevent checkpoint adaptation in response
to a single irreparable DSB, likely due to the inability to localize
Esp1 to the nucleus (Dotiwala et al., 2013; Eapen and Haber,
2013; Zheng et al., 1995).
Surprisingly, low (nontoxic) doses of rapamycin are able to
rescue the lethality associated with prolonged CDC13 inactiva-
tion (Qi et al., 2008). However, the mechanistic details regarding
how TORC1 inhibition rescues cell viability remain elusive. Here
we demonstrate that rapamycin prevents lethality associated
with chronic telomere dysfunction by preventing checkpoint
adaptation and hence inhibiting mitotic progression. We demon-
strate that rapamycin acts via multiple parallel pathways,
including autophagy induction, as previously demonstrated
(Dotiwala et al., 2013; Eapen and Haber, 2013), as well as the
inhibition of Cdc5 activity. In addition, we show that the
longevity-promoting effect of rapamycin in S. cerevisiae is, to
an extent, dependent on an intact DNA damage checkpoint.
We propose that high nutrient levels, which activate TORC1
and in turn promote cell growth, are detrimental in the face of
DNA damage, as they encourage mitotic progression. These
results indicate that TOR inhibitors and dietary control may
have potential benefits in disorders associated with DNA dam-
age and genome instability.
RESULTS
Rapamycin Prevents Checkpoint Adaptation following
Telomere Dysfunction
To induce telomere dysfunction in yeast, we inactivated a tem-
perature-sensitive (ts) allele of the CDC13 gene (cdc13-1) via
incubation at its restrictive temperature of 37C, which leads to
the activation of the DDR and eventual loss of cell viability (Garvik
et al., 1995). Cell death was monitored by the uptake of SYTOX
Green, as previously described (Murakami et al., 2012). After
24 hr at 37C, cell viability was compromised in cdc13-1 cells,
but not in isogenic wild-type cells (Figures 1A and 1C). Strikingly,
rapamycin prevented cell death associated with CDC13 inacti-
vation (Figures 1A and 1C), as previously described (Qi et al.,
2008). Neither CDC13 inactivation nor rapamycin treatment
affected cell viability following a shorter (6 hr) incubation at
37C, suggesting that rapamycin’s protective effects are specific
to prolonged telomere dysfunction (Figures 1B and 1C). Consis-tent with a previous report, rapamycin had no influence on the
accumulation of single-stranded telomeric DNA either at the 6
or 24 hr time point (Figure S1A) following CDC13 inactivation,
indicating that the increased viability is not due to enhanced
telomere protection (Qi et al., 2008).
cdc13-1 cells eventually undergo checkpoint adaptation
following prolonged incubation at 37C (Toczyski et al., 1997).
In our experimental conditions, cdc13-1 haploid cells held at
the restrictive temperature for 6 hr arrested uniformly at the
G2/M border with 2N DNA content, as expected (Figure 1D).
Following prolonged telomere uncapping (24 hr), adaptation
could be observed as cells with 1N (G1 cells) and sub-1N
(dead cells) DNA content became apparent, indicating cell cycle
progression despite the presence of telomere dysfunction
(Figure 1D). We observed dephosphorylation of the checkpoint
kinase Rad53 in adapted cells (24 hr at 37C), along with degra-
dation of the mitotic cyclin Clb2 and accumulation of the cyclin-
dependent kinase inhibitor Sic1, indicative of exit from mitosis
and entry into the followingG1 (Figure 1E). Strikingly, the addition
of rapamycin prevented checkpoint adaptation with cells re-
maining uniformly arrested at the G2/M border with phosphory-
lated Rad53, high levels of Clb2, and no detectable Sic1 (Figures
1D and 1E).
Recovery was assessed by placing cdc13-1 cells back to their
permissive temperature of 23C and analyzing cell viability once
telomere function was restored. cdc13-1 cells that had experi-
enced 6 hr of telomere dysfunction formed colonies similar
to wild-type cells in a recovery assay (Figure 1F). In contrast,
cdc13-1 cells that had undergone adaptation were unable to
recover unless they had been incubated in the presence of rapa-
mycin (Figure 1G). cdc13-1 cells that were kept at the permissive
temperature of 23C for 6 and 24 hr (temperature control cells)
did not experience compromised viability (Figures S1B and
S1C). To ensure that the rapamycin-mediated rescue was not
a result of a selection-bias for suppressors of the cdc13-1muta-
tion, we reinoculated the rescued rapamycin-treated cells and
subjected them to a second round of incubation at 37C. Indeed,
these cells could not recover unless they were also treated with
rapamycin in the repeat experiment, ruling out the possibility
that genetic suppressors accounted for the rapamycin rescue
(Figure S1D). The deletion of TOR1 phenocopied the viability
effects of rapamycin on cdc13-1 cells (Figure S1E), whereas
the deletion of RAS2 (activator of the cyclic AMP pathway) did
not (Figure S1F), demonstrating TORC1 specificity. Rapamycin
and TOR1 deletion also rescued cell death associated with
another CST ts mutant (stn1-13) (Figure S1G). Although active
TORC1 signaling is a potent activator of translation, we were
not able to phenocopy the cdc13-1 rescue effects when the gen-
eral translation inhibitor, cyclohexamide, was substituted for
rapamycin at a concentration (0.1 mg/ml) that prevented cell
growth to an equal extent as 3 nM rapamycin (Figure S1H;
data not shown). We ruled out the effects of TORC1 inhibition
on the G1/S transition by prearresting cdc13-1 cells at the
G2/M border prior to the addition of rapamycin (Figure S1I)
and found that the rapamycin-mediated lethality rescue was
not altered (Figure S1J). Finally, the deletion of SAN1, encoding
the nuclear E3 ubiquitin ligase, did not rescue cdc13-1 in our
experimental conditions (Figure S1K), excluding the notion thatCell Reports 9, 324–335, October 9, 2014 ª2014 The Authors 325
Figure 1. Rapamycin Prevents Checkpoint Adaptation in cdc13-1 Cells
(A and B) Following an overnight culture in YPD at 23C, cells were diluted and shifted to 37C for the indicated times in the presence or absence of rapamycin.
SYTOX Green staining of dead cells followed by FACS scanning determined cell viability. Numbers in the boxes represent % of dead (top) and viable (bottom)
cells, for one representative experiment (FSC = forward scatter).
(C) Quantification of (A) and (B), with data represented as themeans ± SEM of multiple biological replicates (wild-type: 6 hr, n = 4; 24 hr, n = 5; cdc13-1: 6 hr, n = 6;
24 hr, n = 7). The p value was calculated using an unpaired Student’s t test (****p < 0.0001).
(D) Cells from the above experiments were prepared for DNA FACS scan to determine ploidy at the indicated time points. The peaks corresponding to 1N
(G1 cells) and 2N (G2/M cells) are indicated.
(E) Western blot showing phosphorylation of Rad53, as well as Clb2 and Sic1 levels.
(F and G) After 6 (F) and 24 hr (G) at the nonpermissive temperature, the indicated genotypes were spotted as 10-fold serial dilutions on YPD plates and incubated
for 3 days at the permissive temperature of 23C to assess recovery capacity.rapamycin may be promoting the accumulation of the cdc13-1
gene product as has been previously observed in SAN1 deletion
cells (Gardner et al., 2005).326 Cell Reports 9, 324–335, October 9, 2014 ª2014 The AuthorsThese data suggest that TORC1 inhibition may preserve cell
viability following prolonged telomere dysfunction by preventing
checkpoint adaptation.
Figure 2. The Sch9 Kinase Regulates
Checkpoint Adaptation
(A) Recovery capacity was assessed by allowing
cells to regrow at 23C after 24 hr at 37C as in
Figure 1G.
(B) Following an overnight culture in YPD, the
indicated strains were diluted in the presence of
1NM-PP1 and subsequently shifted to 37C for
24 hr before assessing recovery as in Figure 1G.
(C and D) DNA FACS scan (C) and western blotting
(D) depict a failure to adapt in the absence of the
Sch9 kinase.
(E) Cells transformedwith vector control, wild-type
SCH9, or rapamycin nonresponsive SCH92D3E
were grown overnight in SD-Ura and diluted in
YPD in the presence or absence of rapamycin
before being shifted to 37C for 24 hr. Viability
staining (as in Figure 1A) was performed on the
indicated strains, with data represented as the
means ± SEM of three independent experiments;
p values were calculated using a one-way ANOVA
(****p < 0.0001, ***p = 0.0005, **p = 0.0062).Inhibition of the Sch9 Branch of TORC1 Signaling
Prevents Adaptation
Amajoreffector of TORC1 is theAGCkinase,Sch9,which isphos-
phorylated and activated by TORC1 (Urban et al., 2007). To
determine whether rapamycin prevents adaptation through Sch9
inhibition,wecreatedcdc13-1 sch9mutants andassessed recov-
ery following prolongedCDC13 inactivation. Similar to rapamycin
addition, the deletion ofSCH9 prevented cell death following pro-
longed telomere dysfunction (Figure 2A). This effect was recapit-
ulated in an SCH9 analog-sensitive allele (sch9as) (Figure 2B),
where kinase activity is inhibited by the ATP analog, 1NM-PP1
(Huberetal., 2011) (seeFiguresS2AandS2Bfor temperaturecon-
trol experiment). The deletion of SCH9 prevented both cell cycle
progression (Figure2C)andRad53dephosphorylation (Figure2D),
albeit the latter not as efficiently as with rapamycin (Figure 1E),
suggesting that Sch9 is not the only target of rapamycin respon-
sible for maintaining Rad53 activity. In order to test this notion
more rigorously, we performed viability analysis as in Figure 1C.
In accordance with enhanced recovery (Figure 2A), the deletion
of SCH9 rescued cdc13-1 cells in the absence of rapamycin,
and this effect was enhanced in the presence of rapamycin
suggestive of an SCH9-independent pathway (Figure 2E).
To confirm this, we expressed either wild-type SCH9 or an allele
that is no longer inhibited by rapamycin (SCH92D3E) (Urban et al.,
2007) as the only copy of SCH9 in cdc13-1 cells. In both cases,
rapamycin was able to rescue cell viability (Figure 2E), confirming
the presence of SCH9-independent compensatory pathways.
In summary, the inhibition of TORC1 and its effector Sch9
prevents checkpoint adaptation and maintains Rad53 in an
active state. However, other parallel pathways exist, indepen-
dent of Sch9 inhibition, which can promote cell viability upon
rapamycin addition.Cell Reports 9, 324–335Rapamycin Prevents Adaptation in
an Autophagy-IndependentManner
The ectopic activation of autophagy (via
the ATG13-8SA allele) prevents adapta-tion following the induction of a DSB (Dotiwala et al., 2013;
Eapen and Haber, 2013). We observed that ATG13-8SA
expression also prevents cell death in cdc13-1 cells after
24 hr at 37C (Figures 3A and S3A). The recovery was depen-
dent on the presence of Mec1 (Figure 3A), as previously
described (Dotiwala et al., 2013), where it was postulated that
a transient checkpoint-dependent burst of autophagy con-
tributes to cell cycle arrest. Although cells expressing ATG13-
8SA do not adapt, they still experience Rad53 dephosphoryla-
tion (Dotiwala et al., 2013), suggesting that autophagy induction
and Sch9 inhibition prevent adaptation in mechanistically
distinct manners. We assessed the contribution of autophagy
to the rapamycin-mediated inhibition of adaptation by moni-
toring adaptation capacity in either atg5 or atg1 mutants, which
are autophagy defective (Tsukada and Ohsumi, 1993). After
24 hr at the restrictive temperature, rapamycin improved the
viability of cdc13-1 atg5 cells, albeit not to the same extent
as in cdc13-1 single mutants (Figure 3B). Analysis of DNA con-
tent demonstrated that rapamycin prevented adaptation even
in the absence of autophagy (Figure 3C). Consistent with the
notion that autophagy induction is not required to maintain
Rad53 phosphorylation (Dotiwala et al., 2013), Rad53 dephos-
phorylation was still prevented by rapamycin in cdc13-1 atg5
cells (Figure 3D). Rapamycin impaired both Clb2 degradation
and Sic1 accumulation in the presence and absence of auto-
phagy when prolonged telomere dysfunction was induced (Fig-
ure 3D). Moreover, rapamycin treatment of autophagy-deficient
cells that had experienced long-term CDC13 inactivation
rendered them nearly fully recovery competent, as shown for
the deletions of ATG5 (Figures 3E and S3B temperature con-
trol) and ATG1 (Figure S3C). We assessed autophagy activity
in cdc13-1 atg5 mutants using the GFP-Atg8 readout, where, October 9, 2014 ª2014 The Authors 327
Figure 3. Rapamycin Prevents Adaptation in the Absence of Autophagy
(A) Cells harboring the indicated plasmids were grown in raffinose-containing media before being diluted in medium containing 2% galactose to induce ATG13-
8SA and shifted to 37C for 24 hr. Cells were subsequently spotted as in Figure 1G.
(B) Viability staining was performed on the indicated strains, with data represented as the means ± SEM of multiple biological replicates (wild-type n = 3, atg5
n = 3, cdc13-1 n = 4, cdc13-1 atg5 n = 4); p values were calculated using a one-way ANOVA (****p < 0.0001, **p = 0.0036, ns = not significant).
(C and D) DNA FACS scan (C) and western blot analysis (D) demonstrate that checkpoint adaptation is prevented by rapamycin even in cdc13-1 atg5 cells.
(E and F) The indicated strains were spotted onto YPD and allowed to recover at 23C as described in Figure 1G.
(G) Cells transformed with either vector control, wild-type SCH9, or rapamycin nonresponsive SCH92D3E were grown overnight in SD-Ura and diluted in
YPD medium in the presence or absence of rapamycin before being shifted to 37C for 24 hr. Viability staining was performed on the indicated strains, with data
represented as the means ± SEM of three independent experiments; p values were calculated using a one-way ANOVA (****p < 0.0001, ns = not significant).the release of free GFP serves as an indicator for the conver-
sion of autophagosomes to autolysosomes (Klionsky, 2011),
and observed that cdc13-1 atg5 mutants were completely
defective for autophagy in the presence and absence of rapa-
mycin (Figures S3D and S3E). Importantly, the viability rescue328 Cell Reports 9, 324–335, October 9, 2014 ª2014 The Authorsof cdc13-1 cells by the SCH9 deletion is independent of auto-
phagy (Figures 3F and Figure S3F temperature control) in
accordance with the absence of autophagy induction in sch9
mutants (Yorimitsu et al., 2007). The above data (Figures 2
and 3) indicate that rapamycin prevents adaptation via at least
Figure 4. Rapamycin Prevents Adaptation via the Mec1-Rad53 DNA Damage Checkpoint
(A) DNA FACS scan of the indicated strains as in Figure 1D.
(B–E) Recovery was assessed by assessing regrowth at 23C following the incubation at 37C as in Figure 1G.two independent pathways: Sch9 inhibition (Rad53 dependent)
and autophagy induction (Rad53 independent). To determine
if these were the only pathways involved, we combined
the deletion of ATG5 with the rapamycin-resistant SCH92D3E
allele. Surprisingly, we found that cdc13-1 atg5 cells ex-
pressing SCH92D3E could still be rescued by rapamycin (Fig-
ure 3G), suggesting that in addition to Sch9 inhibition and
autophagy induction, rapamycin controls other compensatory
TORC1 effectors that contribute to the inhibition of checkpoint
adaptation.
Rapamycin Requires Mec1 and Rad53 to Prevent
Adaptation
Since Sch9 inhibition prevents Rad53 dephosphorylation (Fig-
ure 2D) and robustly improves the survival of cdc13-1 cells,
we hypothesized that an intact DNA damage checkpoint would
be critical for rapamycin to prevent adaptation. Indeed, rapa-
mycin could not prevent the accumulation of G1 cells following
prolonged telomere uncapping in cells carrying the checkpoint-
defective rad53-11 allele (Weinert et al., 1994) (Figure 4A).
Furthermore, the ability of rapamycin to improve recovery
potential following chronic telomere dysfunction was largely
(but not completely) compromised in both rad53-11 and mec1
mutants (Figures 4B, 4C, and S4A temperature control). Impor-
tantly, cdc13-1 atg1 rad53-11 mutants could also be rescued,
to an extent, by rapamycin treatment (Figure 4D), confirming
the notion that the regulation of multiple TORC1 effectors is
able to promote adaptation in a compensatory manner. In
contrast to the partial rapamycin rescue we see in cdc13-1
rad53-11 cells, loss of Rad53 function completely abolished
the rescue associated with Sch9 inhibition (Figure 4E). In sum-
mary, these data confirm the notion that rapamycin largely
prevents checkpoint adaptation via the maintenance of the
Mec1/Rad53 checkpoint (through Sch9 inhibition) but suggest
that other TORC1 effectors, in addition to autophagy induction,
are also at play.Rapamycin Inhibits Rad53 Dephosphorylation
via Cdc5 Regulation
CDC5 was one of the first genes implicated in promoting check-
point adaptation (Toczyski et al., 1997). The overexpression
of Cdc5 stimulates Rad53 dephosphorylation and accelerates
adaptation (Donnianni et al., 2010; Vidanes et al., 2010). Since
the maintenance of Rad53 activity is critical for rapamycin-
mediated prevention of checkpoint adaptation (Figures 4A and
4B), we tested whether Cdc5 activity may be decreased
following TORC1 inactivation. Following CDC13 inactivation
and subsequent metaphase arrest, Bfa1 (a bona fide Cdc5
target) migrates as a higher molecular weight form due to
Cdc5-dependent phosphorylation (Figure 5A) (Hu et al., 2001;
Valerio-Santiago et al., 2013). In the presence of rapamycin,
Bfa1 phosphorylation was lost both in the presence and
absence of autophagy, suggesting reduced Cdc5 activity (Fig-
ure 5A). Consistent with our previous genetic data, the deletion
of SCH9 also had reduced Cdc5 activity. Analysis of DNA
content via flow cytometry (Figure S5A) combined with the
confirmation that Pds1 was stable (Figure 5A), confirmed that
differences in cell cycle stage were not responsible for the
altered Cdc5 activity. These data suggest that rapamycin, via
Sch9 inhibition, reduces Cdc5 activity in the presence of
dysfunctional telomeres, which may be directly responsible for
the adaptation defect.
If reduced Cdc5 activity is responsible for the rapamycin-
mediated adaptation defect, we reasoned that increasing
Cdc5 activity would drive adaptation even in the presence of
rapamycin. We shifted cdc13-1 cells harboring a galactose
inducible CDC5 vector to the nonpermissive temperature of
30C. Following 2 hr at the nonpermissive temperature, both
galactose and nocodazole were added to induce Cdc5 expres-
sion and simultaneously prevent cells from progressing to the
following G1 phase. Rapamycin was added to half of the culture,
whereas the other half was exposed to an equal volume of the
vehicle control, DMSO (Figure 5B). Already after 2 hr of Cdc5Cell Reports 9, 324–335, October 9, 2014 ª2014 The Authors 329
Figure 5. Cdc5-Induced Adaptation Is Prevented by TORC1 Inhibition
(A) Western blot showing the phosphorylation status of Bfa1. Cells from an overnight culture in YPD at 23C were diluted and shifted to 37C for 3 hr in the
presence or absence of rapamycin.
(B) Scheme of the experimental setup for (C) and (D). Overnight cultures were diluted and shifted to 30C or 37C. Galactosewas added to a concentration of 2%,
and the cultures split into a DMSO or rapamycin-treated culture. Time points were taken as indicated.
(C) Western blot of cdc13-1 cells harboring a Gal-inducible Cdc5 overexpression plasmid treated as in (B), showing phosphorylation of Rad53, as well as Cdc5
expression and Pgk1 as a loading control. Nocodazole was added to a final concentration of 15 mg/ml.
(D) Following the scheme in (B), the indicated strains were spotted onto YPD and allowed to recover at 23C as in Figure 1G.
(E) Cell viability staining was performed on the indicated strains, with data represented as themeans ±SEMofmultiple biological replicates (wild-type n = 3, cdc5-
ad n = 3, cdc13-1 n = 5, cdc13-1 cdc5-ad n = 5); p values were calculated using a one-way ANOVA (****p < 0.0001).
(F) Recovery was assessed by allowing cells to regrow at 23C as in Figure 1G.
(G) DNA FACS scan of the indicated strains as in Figure 1D.
(H) Western blot analysis demonstrates that checkpoint adaptation is prevented in cdc13-1 cdc5-ad cells without rapamycin treatment. Gal, galactose; Noc,
nocodazole.overexpression (4 hr time point), Rad53 was dephosphorylated
(Figure 5C). This rapid dephosphorylation was not prevented in
the presence of rapamycin (Figure 5C), suggesting that rapamy-
cin is preventing adaptation via the inhibition of a Cdc5-medi-
ated process. In agreement, Cdc5 overexpression severely
impaired the recovery capacity associated with cdc13-1 cells
that had been exposed to rapamycin (Figures 5D and S5B
temperature control).330 Cell Reports 9, 324–335, October 9, 2014 ª2014 The AuthorsThe cdc5-ad allele has been characterized as being adap-
tation defective because of a single amino acid mutation
(L251W) (Jin and Wang, 2006; Toczyski et al., 1997). Although
CDC5 is an essential gene, cells harboring the cdc5-ad allele
are not compromised in other aspects of cell growth, suggesting
that the -ad allele is adaptation specific. The presence of the
cdc5-ad allele significantly increased both the viability and
recovery of cdc13-1 cells following a 24 hr incubation at 37C
even in the absence of rapamycin (i.e., phenocopying the rapa-
mycin effects) (Figures 5E, 5F, and S5C temperature control).
The cdc5-ad allele prevented adaptation in terms of cell cycle
progression as well as the maintenance of Rad53 phosphoryla-
tion (Figures 5G and 5H). Therefore, the rapamycin-mediated
regulation of the DNA damage checkpoint via Cdc5 appears
to be important in cells that arrest in G2/M due to telomere
dysfunction.
The further increase in viability upon rapamycin addition in
cdc13-1 cdc5-ad cells (Figure 5E) is consistent with multiple
TORC1 effector pathways (in addition to autophagy induction)
being involved. Indeed, the viability ofcdc13-1 cdc5-adatg5cells
wasstill increasedupon rapamycin addition (FigureS5D).Amajor
effector pathway downstream of TORC1 and parallel to Sch9 is
regulated by the phosphatase inhibitor, Tap42. We inactivated
Tap42 function by using the tap42-11 allele at 37C, thereby
mimicking rapamycin addition (Di Como and Arndt, 1996; Yan
et al., 2006) and found that this was also able to rescue cdc13-
1 cells (Figure S5E). Future work will focus on understanding
mechanistic details of the tap42-11-mediated rescue.
Importantly, we found that many cell division cycle ‘‘cdc’’
mutants that display a G2/M arrest point (Weinert and Hartwell,
1993) were rescued through rapamycin addition and that this
was not a specific effect associated with telomere dysfunction.
Indeed, cdc14-1, cdc15-2, cdc16-1, cdc17-1, and cdc20-1
mutants all had increased viability (to variable extents) and
improved recovery in the presence of rapamycin (Figures S5F
and S5G; note that cdc17-1 mutants do not require Rad9 for
arrest at 38C (Weinert and Hartwell, 1993). In contrast to
cdc13-1 mutants, the cdc5-ad allele was not able to recue
viability in cdc14-1, cdc15-2, cdc16-1, and cdc17-1 cells, while
only a slight rescue could be detected in cdc20-1 mutants,
suggesting that Cdc5-mediated adaptation may be specific for
telomere dysfunction/DNA damage (Figure S5H), as previously
proposed (Valerio-Santiago et al., 2013). The induction of
autophagy, however, was able to rescue lethality in cdc15-2,
cdc16-1, and cdc20-1 mutants (Figure S5I; note that cdc13-1
cells are more viable in the presence of galactose). Importantly,
the rapamycin-mediated rescue of ‘‘cdc’’ mutants was not spe-
cific to a G2/M arrest, as cdc4-1, cdc7-4, and cdc2-2 mutants,
which arrest in either G1 (cdc4-1) or early S can also be rescued,
to variable extents, by inhibiting TORC1 (Figure S5J).
Lifespan Extension via Rapamycin Requires the DNA
Damage Checkpoint
We investigated which nutrient sources, when depleted, would
improve the viability of cells with chronic telomere dysfunction.
Caloric restriction (0.1% glucose) (Figure 6A) as well as leucine
or uracil starvation (Figure 6B) and growth in the presence of
a nonfermentable carbon source (ethanol) (Figure 6C) were all
able to improve the recovery of cdc13-1 cells (see Figures
S6A–S6C for temperature control). Growth in ethanol prevented
cdc13-1 cells from adapting by keeping Rad53 in a phosphory-
lated and active state (Figure S6D), suggesting that nutrient
deprivation prevents checkpoint adaptation in a manner similar
to TORC1 inhibition by rapamycin.
Rapamycin extends lifespan in a variety of model organisms
ranging from yeast to mouse (Cornu et al., 2013; Harrisonet al., 2009; Longo et al., 2012). Similarly, caloric restriction
and other forms of nutrient deprivation can also delay aging-
associated processes (Anderson and Weindruch, 2012; Katewa
and Kapahi, 2010). Our results suggest that rapamycin and
nutrient deprivationmay promote longevity by preventing check-
point adaptation, which would in turn prevent the accumulation
of DNA damage and genetic alterations over time. To test this
hypothesis, we inoculated wild-type and rad53-11 cells in the
presence or absence of rapamycin and assayed cell viability
via SYTOX Green staining over time to assess chronological
aging. As expected, rapamycin decreased the rate of aging in
wild-type cells (Figure 6D). Strikingly, rapamycin was unable to
prevent the loss of viability associated with aging when the
DNA damage checkpoint was impaired in rad53-11 cells (Fig-
ure 6D). The rapamycin antiaging effects, at early time points,
were not dependent on the induction of autophagy, as the rate
of aging was still decreased by rapamycin in atg5 mutant cells
(Figure 6E). Although the DMSO (control)-treated rad53-11 cells
aged similar to wild-type cells over the first 4 days (Figure 6D),
the loss of the checkpoint led to increased aging rates at later
time points, which was prevented to an extent by rapamycin
(Figure S5E). Together, these data suggest that rapamycin pre-
vents chronological aging, at least in part, through reinforcement
of the DNA damage checkpoint.
DISCUSSION
Dysfunctional telomeres activate the DNA damage checkpoint,
which prevents mitotic progression and ensures that damaged
chromosomes are not segregated to daughter cells. Indeed,
the ablation of a single telomere from a yeast chromosome
results in increased loss of the affected chromosome, an effect
that is exacerbated when the DNA damage checkpoint is
impaired (Sandell and Zakian, 1993). Upon DNA damage,
Rad53 (CHK2) inhibits mitosis through inactivation of the mitotic
kinase Cdc5 (Sanchez et al., 1999) (Figure 6F). Inactivation of
Cdc5 hinders mitotic progression via (1) blocking the elongation
of the mitotic spindle during anaphase B (Zhang et al., 2009) and
(2) preventing activation of the MEN (Valerio-Santiago et al.,
2013). Following repair, the checkpoint is inactivated due to
the dephosphorylation of Rad53 and other checkpoint targets,
which allows mitotic progression, referred to as recovery (Harri-
son and Haber, 2006; Keogh et al., 2006; Leroy et al., 2003).
When damage is irreparable, Cdc5 eventually reacquires activity
and inactivates Rad53 (Figure 6F, dashed line 1), which further
relieves Cdc5 inhibition and permits mitotic progression despite
the presence of damaged DNA (checkpoint adaptation) (Fig-
ure 6F, dashed line 2) (Pellicioli et al., 2001; Sandell and Zakian,
1993; Toczyski et al., 1997; van Vugt and Medema, 2004). Cdc5
regulation is critical for adaptation, as the cdc5-ad allele pre-
vents adaptation (Toczyski et al., 1997), and increased Cdc5
levels accelerate it (Donnianni et al., 2010; Vidanes et al.,
2010). Similar to yeast Cdc5, PLK1 has been shown to drive
adaptation following DNA damage in vertebrates (Syljua˚sen
et al., 2006; van Vugt and Medema, 2004; Yoo et al., 2004).
TORC1 activity has been proposed to promote Cdc5 function
(Nakashima et al., 2008). Therefore, cdc13-1 cells held at
nonpermissive temperature are confronted with conflictingCell Reports 9, 324–335, October 9, 2014 ª2014 The Authors 331
Figure 6. Rapamycin Requires Rad53 to Extend Lifespan
(A–C) Cells were grown overnight in YPD before being diluted in the different nutrient conditions as indicated and shifted to 37C for 24 hr. Recovery capacity was
assessed by allowing cells to regrow at 23C as in Figure 1G on YPD.
(D and E) Overnight cultures in YPDwere diluted to OD600 0.1 in SCDmedium and incubated at 30
C. Samples were taken every day for cell viability staining as in
Figure 1A. Graphs represent the means ± SEM of multiple biological replicates (n = 4). WT, wild-type.
(F) Model depicting the pathways by which rapamycin inhibits checkpoint adaptation following prolonged DNA damage (see Discussion).signals in terms of whether or not to proceed through mitosis
(i.e., the DNA damage checkpoint is antimitotic, while high
nutrient conditions via TORC1/Cdc5 function are promitotic).
The checkpoint dominates in the short term, as cells remain
arrested at the G2/M border (Figure 1D). The prevalence of the
checkpoint ensures that cells remain in a viable state and upon
repair are recovery competent (Figure 1F). When telomere
dysfunction is prolonged, the continued signaling from TORC1
eventually prevails, promoting Cdc5-mediated checkpoint
adaptation despite the presence of damage (Figure 6F). The
consequences of checkpoint adaptation include cell death
(Figure 1A), genome instability (Galgoczy and Toczyski, 2001),
and chromosome loss (Sandell and Zakian, 1993).
In the presence of high-nutrient conditions and irreparable
DNA damage, it may be more beneficial for a cell to adapt
in the face of damage to maximize propagation potential in
nutrient-rich conditions than to risk permanent arrest and even-332 Cell Reports 9, 324–335, October 9, 2014 ª2014 The Authorstual cellular senescence. In contrast, when nutrients are limiting,
it is likely more beneficial to remain arrested with DNA damage
than to risk proceeding through mitosis with DNA damage in a
nutrient-poor environment. We speculate that cells have evolved
such signaling crosstalk to maximize overall survival. Indeed, it
has recently been established that crosstalk also exits between
the DNA damage checkpoint and the PKA pathway (Searle et al.,
2004, 2011).
Multiple TORC1 effectors can prevent adaptation, including
Sch9 inhibition, autophagy induction, and presumably Tap42
inactivation (Figure 6F). Sch9 inhibition decreases Cdc5 activity
(Figure 5A) and hence prevents Rad53 inactivation (Figures 2D
and 6F). Autophagy induction does not prevent adaptation
through Rad53 activity (Figure 3D) and likely prevents mitosis
by inhibiting other mitotic events as previously proposed (Doti-
wala et al., 2013). Since the deletion of SCH9 does not prevent
Rad53 dephosphorylation as completely as either rapamycin
addition or the presence of the cdc5-ad allele, we speculate that
Tap42 may also regulate Cdc5 activity as depicted in Figure 6F
(gray lines), although we cannot exclude the possibility that other
mitotic processes may be targeted. It has been reported that
PP2A (a Tap42-regulated phosphatase) is required for the nu-
clear accumulation of Cdc5 (Nakashima et al., 2008). Therefore,
the combined inhibition of Sch9 and Tap42 may be required for
the complete inactivation of Cdc5. Tap42 has also been demon-
strated to negatively regulate autophagy (Yorimitsu et al., 2009),
which likely accounts for a portion of the tap42-11-mediated
rescue of cdc13-1 mutants (Figure 6F).
Many temperature-sensitive ‘‘cdc’’ mutants (Weinert and
Hartwell, 1993) that arrest in a checkpoint-dependent manner
at various cell cycle stages have increased viability in the
presence of rapamycin (Figure S5F). We speculate that high
TORC1 activity overrides checkpoints and promotes down-
stream cell cycle events before the successful completion of
critical upstream events. Importantly, only cdc13-1 cells are
rescued by the presence of the cdc5-ad allele (Figure S5H),
whereas many (but not all) of the G2/M mutants can be rescued
through autophagy induction (Figure S5I). Therefore, TORC1
activity may also be responsible for checkpoint adaptation
in the absence of DNA damage; however, the regulation of
Rad53 via Cdc5 activity is specific for dysfunctional telomeres.
Reducing TORC1 activity has the ability to extend healthy life-
span (Alic and Partridge, 2011; Bjedov and Partridge, 2011).
Furthermore, the inhibition of both TORC1 and Sch9 improves
genome integrity and hence longevity in aged budding yeast
(Madia et al., 2007; Madia et al., 2008, 2009). We have demon-
strated that the increased longevity phenotype imparted by ra-
pamycin is, at least in part, dependent on the DNA damage
checkpoint (Figure 6D). We interpret these data to suggest that
TORC1 inactivation prevents cell cycle progression when
spontaneous DNA lesions/dysfunctional telomeres arise during
aging (Figure 6F). In the presence of rapamycin, only proper
repair followed by recovery would allow cells to proceed through
mitosis. This would have the overall effect of decreasing age-
associated genome instability. TORC1 inhibition may therefore
provide relevant therapeutic alternatives for diseases associated
with genome instability and age. Indeed, sgs1 mutants, which
recapitulate many phenotypes associated with Werner and
Bloom syndrome, are rescued in terms of rapid aging, mutation
frequency, and gross chromosomal rearrangements upon
deletion of SCH9 (Madia et al., 2008).EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids
Strains and plasmids used in this study are listed in Tables S1 and S2, respec-
tively. Haploid strains were derived from the listed diploids in Table S1.Adaptation Assay
An overnight culture at 23C of the indicated strains in yeast extract peptone
dextrose (YPD) medium was diluted to OD600 0.3. Rapamycin (BioChemica)
diluted in DMSOwas added to the indicated final concentration, and the corre-
sponding volume of DMSO was added to the control flasks. Cells were shifted
to 37C, and time points were taken after 6 and 24 hr. Samples were taken for
spotting assays, FACS viability staining, FACS DNA staining, and protein
extraction for western blotting (see Supplemental Experimental Procedures).FACS Viability Staining
The viability staining protocol was modified from Murakami et al. (2012). In
detail, culture volumes corresponding to 0.68 OD600 units were collected by
centrifugation at 7,000 rpm for 1 min. Pelleted cells were washed in 50 mM
sodium citrate (pH 7.4) and spun down at 7,000 rpm for 1 min. Cells were
then resuspended in 1 ml 50 mM sodium citrate (pH 7.4) containing 0.5 mM
SYTOX Green (Life Technologies). Cells were kept dark, sonicated briefly,
and immediately analyzed on a BD FACSCanto II flow cytometer using the
following filters and settings: forward scatter (FSC) and side scatter (SSC)
were detected with a 488 nm laser with detector settings of 350 and 230 V,
respectively; SYTOX Green was detected with a 502 nm long-pass filter and
530/30 nm band-pass filter at 370 V. In each run, 20,000 events per sample
were analyzed. Data collection and analysis were performed using the BD
FACSDiva software and the FlowJo v.10.0.6 (Miltenyi Biotec) software.
Statistical Analysis of Viability Staining
For statistical analysis of cell viability, a gate was set using the FlowJo v.10.0.6
(Miltenyi Biotec) software that contained R98% viable cells for the wild-type
cell population in the DMSO sample after 24 hr at 37C. This gate also included
100% of unstained cells (no SYTOX Green) and was applied to all further
measurements. Since the measurements of the percentage of viable cells
had different standard deviations (SDs) in the different experimental settings,
the data were transformed by calculating the logarithm to base 10 of
(100%  viable cells [in%])/100%. When comparing only two factors, an un-
paired Student’s t test was performed on the transformed data. When four fac-
tors were analyzed, two-way ANOVAwith factors ‘‘genotype’’ and ‘‘treatment’’
and interaction was performed on the transformed data. Comparison of the
four groupswas then done by one-way ANOVA and subsequent pairwise com-
parisons with Bonferroni adjustment for multiple comparisons.
Chronological Lifespan Measurements
The chronological lifespan assay protocol was adapted from Fabrizio and
Longo (2007). An overnight culture of the indicated strains in YPD was diluted
to OD600 = 0.1 in 20 ml SDC medium (SD complete + 43 His, Leu, Met, Ura) in
100 ml flasks. Rapamycin (BioChemica) diluted in DMSO was added to a final
concentration of 10 nM, and the corresponding volume of DMSO was added
to the control flasks. Cells were incubated at 30C, shaking at 230rpm, and
samples were taken for viability measurements every day. The viability staining
protocol was used as described above, with the following adjustments to
circumvent the poor pelleting in synthetic medium: cells were spun for 2 min
at 7,000 rpm. The wash step was omitted, and the cells were directly resus-
pended in 50 mM sodium citrate (pH 7.4) containing 0.5 mM SYTOX Green
(Life Technologies).
For flow cytometry and western blotting protocols, please see the Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.08.053.
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